Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gemini Therapeutics Inc (GMTX)

Gemini Therapeutics Inc (GMTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,493
  • Shares Outstanding, K 43,328
  • Annual Sales, $ 0 K
  • Annual Income, $ -71,870 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta -0.12
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.56
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.00
  • Most Recent Earnings $-0.08 on 11/10/22
  • Next Earnings Date 11/21/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +243,758.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1800 +14.41%
on 12/28/22
1.7300 -21.97%
on 12/05/22
-0.3800 (-21.97%)
since 11/29/22
3-Month
1.1800 +14.41%
on 12/28/22
2.1000 -35.71%
on 10/26/22
-0.1700 (-11.18%)
since 09/29/22
52-Week
1.1600 +16.38%
on 03/01/22
3.1500 -57.14%
on 12/30/21
-1.5300 (-53.13%)
since 12/29/21

Most Recent Stories

More News
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigation

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of FS Development Corp., which merged with Gemini Therapeutics, Inc. ("Gemini" or "the...

GMTX : 13.5000 (unch)
Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria

/PRNewswire/ -- Disc Medicine, Inc. ("Disc"), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

GMTX : 13.5000 (unch)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, SAFE, STAR, ADES

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

GMTX : 13.5000 (unch)
SAFE : 19.51 (-1.27%)
STAR : 55.32 (+2.01%)
ADES : 3.36 (+3.07%)
Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)

/PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for...

GMTX : 13.5000 (unch)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFY

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

GMTX : 13.5000 (unch)
FMTX : 20.01 (+0.15%)
TRQ : 31.41 (-0.91%)
SGFY : 30.49 (+0.07%)
GEMINI THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. - GMTX

/PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the...

GMTX : 13.5000 (unch)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RCKT, RCOR, EVOP, GMTX

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

RCKT : 11.56 (+1.85%)
RCOR : 3.20 (+4.92%)
EVOP : 33.99 (+0.38%)
GMTX : 13.5000 (unch)
SHAREHOLDER ALERT: Weiss Law Reminds STOR, AVLR, LOTZ, and GMTX Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

STOR : 32.21 (unch)
AVLR : 93.48 (+0.03%)
LOTZ : 0.1480 (-1.99%)
GMTX : 13.5000 (unch)
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates GMTX, RMED, LOTZ

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

GMTX : 13.5000 (unch)
RMED : 0.5940 (+10.00%)
LOTZ : 0.1480 (-1.99%)
SHAREHOLDER ALERT: Weiss Law Reminds AVLR, LOTZ, GMTX, and AAWW Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

AVLR : 93.48 (+0.03%)
LOTZ : 0.1480 (-1.99%)
GMTX : 13.5000 (unch)
AAWW : 102.48 (+0.02%)

Business Summary

Gemini Therapeutics Inc. is a clinical stage precision medicine company. It engages in developing novel therapeutic compounds to treat genetically defined age-related macular degeneration. The company's lead candidate principally includes GEM103. Its pipeline includes recombinant proteins, gene therapies...

See More

Key Turning Points

3rd Resistance Point 1.4500
2nd Resistance Point 1.4300
1st Resistance Point 1.3900
Last Price 13.5000
1st Support Level 1.3300
2nd Support Level 1.3100
3rd Support Level 1.2700

See More

Last Price 13.5000
52-Week High 3.1500
Fibonacci 61.8% 2.3898
Fibonacci 50% 2.1550
Fibonacci 38.2% 1.9202
52-Week Low 1.1600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar